使用地舒单抗治疗成软骨细胞瘤：附一例对 RANK 信号通路作用的相关分析。
Treatment of Chondroblastoma with Denosumab: A Case Report with a Correlative Analysis of Effect on the RANK Signaling Pathway.
机构信息
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina.
Duke Cancer Institute, Durham, North Carolina.
出版信息
JBJS Case Connect. 2021 May 17;11(2):01709767-202106000-00071. doi: e20.00178.
CASE
A 15-year-old boy with chondroblastoma of the right hemipelvis presented with significant periacetabular bone destruction. Neoadjuvant denosumab treatment facilitated initial joint preserving surgery. Unfortunately, he experienced 2 local recurrences and underwent wide surgical resection 2 years after his initial diagnosis.
CONCLUSION
Inhibition of the receptor activator of NF-κB (RANK)/RANK ligand (RANK-L) pathway with denosumab has been used neoadjuvantly for the treatment of giant cell tumor of bone, but its role in the treatment of chondroblastoma is less understood. This patient's clinical response and effect on cellular RANK/RANK-L activity support the consideration of denosumab in the treatment algorithm for other osteolytic bone tumors such as chondroblastoma.
病例
一名 15 岁男孩患有右侧髋骨软骨母细胞瘤，表现为明显的髋臼周围骨破坏。新辅助地舒单抗治疗有助于初始保关节手术。不幸的是，他经历了 2 次局部复发，并在初次诊断后 2 年接受了广泛的手术切除。
结论
用地舒单抗抑制核因子-κB 受体激活剂（RANK）/RANK 配体（RANK-L）通路已被用于治疗骨巨细胞瘤的新辅助治疗，但在软骨母细胞瘤治疗中的作用了解较少。该患者的临床反应和对细胞 RANK/RANK-L 活性的影响支持在治疗算法中考虑地舒单抗用于治疗其他溶骨性骨肿瘤，如软骨母细胞瘤。
Zotero 插件